SCHEMBL17479057

SCHEMBL17479057

O=S(=O)(c1cccc(-c2nc3cc(Cl)ccc3o2)c1)N(CCCN1CCOCC1)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP3 Q9Y6F1 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ USP2 O75604 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ AHR P35869 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ TMEM97 Q5BJF2 3/20 0.41
▸ CASR P41180 1/20 0.40
▸ DRD2 P14416 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ FBP1 P09467 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ SENP7 Q9BQF6 1/20 0.38
▸ SENP6 Q9GZR1 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479795 0.86 SMN1; SMN2 (0.45) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479006 0.86 SMN1; SMN2 (0.43) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479791 0.86 KDM4E (0.42) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479172 0.86 SMN1; SMN2 (0.42) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479698 0.84 SMN1; SMN2 (0.44) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479697 0.77 MAPK1 (0.38) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479705 0.76 HSD17B10 (0.42) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479741 0.73 KDM4E (0.38) SMN1; SMN2USP2KDM4EHPGDMAPK1
SCHEMBL17479191 0.73 ALDH1A1 (0.52) SMN1; SMN2USP2MAPK1MAPTNPC1
SCHEMBL17479721 0.71 MAPK1 (0.56) SMN1; SMN2USP2KDM4EHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP claimed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US claimed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US claimed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP claimed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO claimed
CN-107001283-B FLT3 receptor antagonists 国家健康与医学研究院 2021-05-25 — — CN disclosed
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-06-04 — — US disclosed
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP disclosed
EP-3624780-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-03-25 — — EP disclosed
WO-2018211018-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-11-22 — — WO disclosed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US disclosed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US disclosed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP disclosed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS FLT3, CSF1R, CSF3R PARP3 1545/4885SMN1; SMN2 3517/4885USP2 3980/4885
US-10065937-B2 FLT3 receptor antagonists FLT3, CSF1R, CSF3R PARP3 1545/4885SMN1; SMN2 3517/4885USP2 3980/4885
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS FLT3, CSF1R, OPRL1 PARP3 1950/4885SMN1; SMN2 3037/4885USP2 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback